C. R. Bard | Evaluate

December 11, 2018

The FDA’s proposed changes to device regulation are thin on detail

The FDA has made a lot of noise about its plans to make medical devices safer. But these plans are somewhat amorphous; any meaningful steps would likely require congressional approval, and could thus take years.

Boston and Coloplast sink on mesh mess

The FDA’s proposed changes to device regulation are thin on detail

Luck, strategy and FDA device approvals

Interview – Serial acquirer Teleflex seeks deals both big and small

Top 20 medtechs jockey for position, but their overall share will drop

Startling reversal of fortunes as large-cap medtechs soar

Snippet roundup: Novartis enters Advair generic race, Biogen dealt CFO blow

The return of medtech scale-building?

Political ructions, poor deal-making and scandal – a bad year for big-cap medtechs

Sun comes out for big-cap medtechs as investors seek refuge from market squalls

Medtech news over the Christmas period 2016

Latest Reports

Pharma Market Drivers Part Three: Blowin’ in the wind

Q3 Round Up: Alive but not kicking report

Editor's Picks

Lecanemab can; now the wait for details begins

The gloom deepens for biopharma stocks

SITC 2022 preview – cytokines and oral checkpoints

Big pharma’s key fourth-quarter data

TCT 2022 – Otsuka’s renal denervation system shines